• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

死亡受体5细胞外结合结构域在存在和不存在激活配体肿瘤坏死因子相关凋亡诱导配体(TRAIL)情况下的构象:一项分子动力学研究

The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study.

作者信息

Wassenaar Tsjerk A, Quax Wim J, Mark Alan E

机构信息

Groningen Biomolecular Sciences and Biotechnology Institute (GBB), Department of Biophysical Chemistry, University of Groningen, 9747AG Groningen, The Netherlands.

出版信息

Proteins. 2008 Feb 1;70(2):333-43. doi: 10.1002/prot.21541.

DOI:10.1002/prot.21541
PMID:17671978
Abstract

The Death Receptor 5 (DR5), a member of tumor necrosis factor receptor (TNFR) superfamily of receptors, triggers apoptosis (programmed cell death) when stimulated by its tridentate ligand TRAIL. Until recently it was generally assumed that the activation of DR5 resulted from the recruitment of three independent receptor units, leading to the trimerization of intracellular domains. However, there is mounting evidence to suggest that, in the absence of ligand, such cytokine receptors primarily reside as preformed complexes. In this work, molecular dynamics simulations of the TRAIL-DR5 complex, the unbound receptor trimer and individual receptor monomers are compared to gain insight in the mechanism of activation. The results suggest that, in the absence of TRAIL, DR5 has a strong propensity to self-associate and that this is primarily mediated through interactions of the membrane proximal domains. The association of the free receptors leads to a loss of the threefold symmetry found within the receptor-ligand complex. The simulations suggest that the primary role of TRAIL is to induce threefold-symmetry within the DR5 complex and to constrain the receptor to a specific conformation. The implications of this in terms of the mechanism by which the receptor switches from an inactive to an active state are discussed.

摘要

死亡受体5(DR5)是肿瘤坏死因子受体(TNFR)超家族受体的成员之一,当受到其三齿配体TRAIL刺激时,会引发细胞凋亡(程序性细胞死亡)。直到最近,人们普遍认为DR5的激活是由于三个独立受体单元的募集,导致细胞内结构域三聚化。然而,越来越多的证据表明,在没有配体的情况下,这种细胞因子受体主要以预先形成的复合物形式存在。在这项工作中,对TRAIL-DR5复合物、未结合的受体三聚体和单个受体单体进行了分子动力学模拟,以深入了解激活机制。结果表明,在没有TRAIL的情况下,DR5具有很强的自我缔合倾向,这主要是通过膜近端结构域的相互作用介导的。游离受体的缔合导致受体-配体复合物中发现的三重对称性丧失。模拟结果表明,TRAIL的主要作用是在DR5复合物中诱导三重对称性,并将受体限制在特定构象。本文讨论了这在受体从无活性状态转变为活性状态的机制方面的意义。

相似文献

1
The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study.死亡受体5细胞外结合结构域在存在和不存在激活配体肿瘤坏死因子相关凋亡诱导配体(TRAIL)情况下的构象:一项分子动力学研究
Proteins. 2008 Feb 1;70(2):333-43. doi: 10.1002/prot.21541.
2
Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.肿瘤坏死因子相关凋亡诱导配体(TRAIL)与死亡受体5(DR5)复合物的结构揭示了凋亡起始阶段特异性的作用机制。
Nat Struct Biol. 1999 Nov;6(11):1048-53. doi: 10.1038/14935.
3
Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.罗格列酮通过活性氧介导的死亡受体5上调和c-FLIP下调促进肿瘤坏死因子相关凋亡诱导配体诱导的细胞凋亡。
Free Radic Biol Med. 2008 Mar 15;44(6):1055-68. doi: 10.1016/j.freeradbiomed.2007.12.001. Epub 2007 Dec 8.
4
CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.CCAAT/增强子结合蛋白同源蛋白依赖性死亡受体5的诱导以及泛素/蛋白酶体介导的细胞FLICE抑制蛋白下调,有助于二甲基塞来昔布增强人非小细胞肺癌细胞中肿瘤坏死因子相关凋亡诱导配体诱导的凋亡。
Mol Pharmacol. 2007 Nov;72(5):1269-79. doi: 10.1124/mol.107.037465. Epub 2007 Aug 7.
5
Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.生成对死亡受体5具有更高选择性的新型TRAIL突变体DR5-A和DR5-B。
Apoptosis. 2009 Jun;14(6):778-87. doi: 10.1007/s10495-009-0349-3.
6
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.三氧化二砷通过CCAAT/增强子结合蛋白同源蛋白依赖性上调死亡受体5,使人类胶质瘤细胞而非正常星形胶质细胞对肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导的凋亡敏感。
Cancer Res. 2008 Jan 1;68(1):266-75. doi: 10.1158/0008-5472.CAN-07-2444.
7
TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.乳腺癌细胞对肿瘤坏死因子相关凋亡诱导配体(TRAIL)的抗性与死亡受体4和5的组成型内吞作用有关。
Mol Cancer Res. 2008 Dec;6(12):1861-71. doi: 10.1158/1541-7786.MCR-08-0313.
8
Screening of a novel octamer peptide, CNSCWSKD, that induces caspase-dependent cell death.一种新型八聚体肽CNSCWSKD的筛选,该肽可诱导半胱天冬酶依赖性细胞死亡。
Biochem Biophys Res Commun. 2007 Nov 3;362(4):1063-8. doi: 10.1016/j.bbrc.2007.08.110. Epub 2007 Aug 28.
9
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.通过增强对其死亡受体的亲和力来提高重组人肿瘤坏死因子相关凋亡诱导配体(rhTRAIL)的抗肿瘤特性。
Biochemistry. 2009 Mar 17;48(10):2180-91. doi: 10.1021/bi801927x.
10
Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.蛋白酶体抑制剂上调DR5可有效使胶质瘤细胞对TRAIL诱导的凋亡敏感。
FEBS J. 2008 Apr;275(8):1925-36. doi: 10.1111/j.1742-4658.2008.06351.x. Epub 2008 Mar 13.

引用本文的文献

1
Ligand recognition by 14-3-3 proteins requires negative charges but not necessarily phosphorylation.14-3-3蛋白对配体的识别需要负电荷,但不一定需要磷酸化。
FEBS Lett. 2025 Mar;599(6):838-847. doi: 10.1002/1873-3468.15077. Epub 2025 Jan 5.
2
Negative Charges, Not Necessary Phosphorylation, are Required for Ligand Recognition by 14-3-3 Proteins.14-3-3蛋白识别配体需要负电荷,而非磷酸化。
bioRxiv. 2024 Nov 12:2024.09.16.613320. doi: 10.1101/2024.09.16.613320.
3
Receptor Specificity Engineering of TNF Superfamily Ligands.
肿瘤坏死因子超家族配体的受体特异性工程
Pharmaceutics. 2022 Jan 13;14(1):181. doi: 10.3390/pharmaceutics14010181.
4
Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy.TRAIL分子结构在受体寡聚化和信号传导中的重要性。对癌症治疗的启示。
Cancers (Basel). 2019 Mar 29;11(4):444. doi: 10.3390/cancers11040444.
5
Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis.致癌性p95HER2/611CTF使人类乳腺上皮细胞对代谢应激诱导的FLIP下调和TRAIL-R/半胱天冬酶-8依赖性凋亡激活产生预适应。
Oncotarget. 2017 Oct 3;8(55):93688-93703. doi: 10.18632/oncotarget.21458. eCollection 2017 Nov 7.
6
Molecular dynamics study of the effect of active site protonation on Helicobacter pylori 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase.活性位点质子化对幽门螺杆菌5'-甲硫基腺苷/S-腺苷高半胱氨酸核苷酶影响的分子动力学研究
Eur Biophys J. 2015 Dec;44(8):685-96. doi: 10.1007/s00249-015-1067-0. Epub 2015 Aug 8.
7
Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.用 TRAIL 死亡受体 DR5 DNA 疫苗接种诱导三阴性乳腺癌的促凋亡抗体。
Int J Cancer. 2012 Dec 1;131(11):2562-72. doi: 10.1002/ijc.27534. Epub 2012 Apr 24.
8
Hexapeptide fragment of carcinoembryonic antigen which acts as an agonist of heterogeneous ribonucleoprotein M.癌胚抗原的六肽片段,作为异质核糖核蛋白 M 的激动剂。
J Pept Sci. 2012 Apr;18(4):252-60. doi: 10.1002/psc.2393. Epub 2012 Mar 6.
9
Combined modality therapy with TRAIL or agonistic death receptor antibodies.联合 TRAIL 或激动型死亡受体抗体的联合治疗模式。
Cancer Biol Ther. 2011 Mar 1;11(5):431-49. doi: 10.4161/cbt.11.5.14671.
10
Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.靶向死亡受体 5 的新型 N 末端表位触发肿瘤细胞死亡。
J Biol Chem. 2010 Mar 19;285(12):8953-66. doi: 10.1074/jbc.M109.070680. Epub 2010 Jan 27.